US-based gene therapy company Spark Therapeutics has reported $25.2m in revenue, $80.2m in net income and $2.15 basic income per common share in the second quarter (Q2) of 2018.

By comparison, in Q2 2017 the company recorded a net loss of $74.4m, a drop of $2.40 per common share.

Spark Therapeutics’ growth in revenue and income in Q2 was driven by $4.3m in sales from Luxturna, a drug launched in the US during Q2 to treat inherited retinal disease, with 12 vials being used to treat patients in six centres. This was also helped by a $20.9m payment from agreements with Pfizer over drug candidates SPK-9001 for haemophilia B, compared to $1.5m in Q2 2017 and sale of priority review voucher to Jazz Pharmaceuticals for $110m.

During Q2 the company initiated a phase 3 trial with SPK-9001, as well as a phase 1/2 trial for SPK-8011, indicated to treat haemophilia A.

Spark Therapeutics chief executive officer Jeffrey D. Marrazzo said: “We had a strong second quarter, starting with the shipment of 12 vials of Luxturna (voretigene neparvovec-rzyl), as well as the work that went into the completion in early July of the transition to Pfizer and Phase 3 initiation of SPK-9001 for haemophilia B, now known as fidanacogene elaparvovec.

“In addition, based on the totality of the data in our Phase 1/2 clinical trial of investigational SPK-8011 for hemophilia A, we are pleased to announce our plans to initiate a Phase 3 run-in study in the fourth quarter of 2018.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the first half (H1) 2018, the company recorded $40.8m in revenue, $33.8m in net income and $0.91 basic income per common share, compared with a net loss of $126.6m and a decline of $4.10 per common share in H1 2017.

Luxturna contributed $6.7m to revenue in H1, while agreements with Pfizer added $34.1m. These agreements contributed $2.8m to revenue in H1 2017.